» Articles » PMID: 38427622

Behavioral Sensitization and Tolerance Induced by Repeated Treatment with Ketamine Enantiomers in Male Wistar Rats

Overview
Journal PLoS One
Date 2024 Mar 1
PMID 38427622
Authors
Affiliations
Soon will be listed here.
Abstract

Ketamine has gained significant attention as a fast-acting antidepressant. However, ketamine is also associated with undesirable side effects. In our preclinical study, we explored the behavioral effects of ketamine enantiomers at subanesthetic doses. During repeated intermittent treatment, we examined locomotor stimulation and sensitization, ataxia, and expression of natural behaviors (grooming and rearing). Male Wistar rats were subcutaneously treated repeatedly with either 5 mg/kg of R-ketamine or S-ketamine, 15 mg/kg of R-ketamine, S-ketamine or racemic ketamine, 30 mg/kg of racemic ketamine or saline every third day for three weeks (seven treatments overall). After the first treatment, only 15 mg/kg of S-ketamine induced locomotor stimulation, and both 15 mg/kg of S-ketamine and 30 mg/kg of racemic ketamine induced ataxia. Upon repeated administration, doses of 15 mg/kg of R-ketamine, S-ketamine, and racemic ketamine, as well as 30 mg/kg of racemic ketamine, stimulated locomotion. 15 mg/kg of R-ketamine, S-ketamine, and racemic ketamine additionally resulted in locomotor sensitization. The last administration of 15 mg/kg of S-ketamine, 15 mg/kg of racemic ketamine, and 30 mg/kg of racemic ketamine resulted in ataxia. In the case of 15 mg/kg of S-ketamine, ataxic effects were significantly weaker in comparison to the effects from the first administration, indicating tolerance. Natural behaviors were attenuated after 5 and 15 mg/kg of S-ketamine and 15 and 30 mg/kg of racemic ketamine. Neither of the R-ketamine doses produced such an effect. We conclude that S-ketamine has a stronger behavioral effect than R-ketamine.

Citing Articles

()-(-)-Ketamine: The Promise of a Novel Treatment for Psychiatric and Neurological Disorders.

Shafique H, Demers J, Biesiada J, Golani L, Cerne R, Smith J Int J Mol Sci. 2024; 25(12).

PMID: 38928508 PMC: 11203826. DOI: 10.3390/ijms25126804.

References
1.
Javid M, Rahimi M, Keshvari A . Dissociative conscious sedation, an alternative to general anesthesia for laparoscopic peritoneal dialysis catheter implantation: a randomized trial comparing intravenous and subcutaneous ketamine. Perit Dial Int. 2011; 31(3):308-14. DOI: 10.3747/pdi.2010.00110. View

2.
Bahji A, Vazquez G, Zarate Jr C . Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis. J Affect Disord. 2020; 278:542-555. PMC: 7704936. DOI: 10.1016/j.jad.2020.09.071. View

3.
Zhang J, Li S, Hashimoto K . R (-)-ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine. Pharmacol Biochem Behav. 2013; 116:137-41. DOI: 10.1016/j.pbb.2013.11.033. View

4.
Cui J, Ju X, Lee Y, Hong B, Kang H, Han K . Repeated ketamine anesthesia during neurodevelopment upregulates hippocampal activity and enhances drug reward in male mice. Commun Biol. 2022; 5(1):709. PMC: 9287305. DOI: 10.1038/s42003-022-03667-4. View

5.
Fukumoto K, Toki H, Iijima M, Hashihayata T, Yamaguchi J, Hashimoto K . Antidepressant Potential of ()-Ketamine in Rodent Models: Comparison with ()-Ketamine. J Pharmacol Exp Ther. 2017; 361(1):9-16. DOI: 10.1124/jpet.116.239228. View